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Abstract The genes for human and mouse Suppressor of Fused
(SU(FU)/Su(Fu)) in the Hedgehog signaling pathway were
characterized and found to contain 12 exons. Human SU(FU)
localized on chromosome 10q24^25 between the markers
D10S192 and AFM183XB12. We detected three additional
SU(FU) isoforms, two of which have lost their ability to interact
with the transcription factor GLI1. Expression analysis using
whole mount in situ hybridization revealed strong expression of
Su(Fu) in various mouse embryonic tissues. SU(FU) was
considered a candidate gene for the split-hand/split-foot mal-
formation type 3 (SHFM3). However, no alterations in the
SU(FU) gene were found in SHFM3 patients. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
The determination of the function of the Hedgehog signal-
ing pathway in vertebrates is of considerable biological inter-
est [1]. Recently, one additional component of this system,
called the Suppressor of Fused (Su(Fu)) in Drosophila [2],
has been identi¢ed in human [3,4], mouse [3,5,6], and chicken
[7]. In Drosophila, Su(Fu) has been shown to form a complex
with three other molecules, Fused (Fu) [8], Costal-2 (Cos2)
and the transcription factor Cubitus interruptus (Ci) [9] that
all are involved in the transduction of the Hedgehog signal.
This complex associates with microtubules in the absence of
Su(Fu) [10]. The human and chicken Su(Fu) are also able to
bind to the Ci homolog GLI1 [3,7] and to the Drosophila Ci
and Fu [5,7]. Furthermore, Su(Fu) has been shown to bind
GLI1 and GLI3 in the nucleus and to enhance their binding
to their recognition site on DNA [3,7]. The Hedgehog signal-
ing pathway is further in£uenced by transcriptional regulation
of Patched and Gli by Gli itself [11], and by the proteolytic
generation of Ci/Gli isoforms with opposite transactivation
properties [12^14].
Because of its chromosomal localization, biological func-
tion and expression pattern, SU(FU) is considered a candi-
date for the gene mutated in the hereditary disorder split-
hand/split-foot malformation type 3 (SHFM3, OMIM
#600095). This rare condition is transmitted as an autosomal
dominant trait and characterized by an enlargement of the
median cleft and degeneration and fusion of the middle digits.
The chromosomal locus for SHFM3 is 10q24^25 [15^17]. The
human SHFM3 is mirrored by a mouse condition called dac-
tylaplasia (Dac) [18] that results in a similar phenotype. The
Dac gene is mapped to chromosome 19 [19], which is syntenic
to chromosome 10 in human, and it has been proposed that
SHFM3 and Dac might be caused by mutations in corre-
sponding genes [19]. Recently, the Dac mutation was identi-
¢ed as an alteration in the previously unknown F-Box/WD40
gene Dactylin [20]. At the same time, the human homolog for
Dactylin was also published [21] but for the human DACTY-
LIN a link to SHFM3 is not yet demonstrated.
In order to gain insight into the expression and regulation
of SU(FU)/Su(Fu), we have determined the genomic organi-
zation and chromosomal localization of the human and
mouse genes, and analyzed the expression pattern in human
tissues and during mouse embryogenesis. We have also ana-
lyzed SHFM3 patients for mutations in SU(FU).
2. Materials and methods
2.1. Biological materials
Timely mated NMRI mice were from Charles River Laboratories.
The partially overlapping bacterial arti¢cial chromosome (BAC)
clones RPCI-11-170J3 containing the 5P-end and 243I14 containing
the 3P-end of the human SU(FU) gene were from Research Genetics.
The mouse Su(Fu) BAC clones 17985 and 17986 were from Incyte
Genomics, Inc. The mouse Su(Fu) EST clones 513730, 1195307,
1224813, and 963990 from the IMAGE consortium were from the
UK HGMP Resource Centre, Hinxton, Cambridge, UK.
2.2. Patients
Patients with SHFM3 were members of families previously linked
to chromosome 10q24^25 [16].
2.3. Chromosomal localization, mapping, and sequencing of the human
SU(FU) and mouse Su(Fu) genes
The chromosomal localization of SU(FU) was determined by radi-
ation hybrid mapping using the two primer pairs 5P-CAGTTGTGTC-
AACGAGATCTCC-3P/5P-CTGTGGCCTGTGCATGGCAC-3P and
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5P-CCGCTGGCTAAGCCTTGTGAC-3P/5P-CAGGGTCCAGAGT-
CAAACCTCA-3P on the Genbridge G4 map (Research Genetics).
The exon^intron borders were determined by sequencing BACs. Re-
striction enzyme digests of BAC DNA and subcloned DNA fragments
were transferred to Hybond N ¢lters (Amersham) and hybridized
with radiolabeled oligonucleotide probes for individual exons to as-
semble the Su(Fu) locus map.
2.4. Screening for mRNA variants
cDNAs from normal human tissues (human MTC panel II) or from
xenografted human tumors (human tumor MTC panel) were from
Clontech. For mouse embryo cDNA, organs were homogenized and
RNA was extracted using RNAzol B (Tel-Test, Inc.). Subsequently,
cDNA was prepared using oligo-(dT) and reverse transcriptase (RT;
Clontech). Polymerase chain reaction (PCR) products were generated
containing the entire coding region of SU(FU)/Su(Fu). Subsequently,
nested PCR products containing exons 2^3, 4^5, 6^7, 8^9, and 10^11,
respectively, were obtained. After gel electrophoresis, variant tran-
scripts were detected by size di¡erence.
2.5. Whole mount in situ hybridization
Mouse embryos were cut sagitally and after ¢xation in 4% para-
formaldehyde hybridized according to standard procedures [22]. Di-
goxin-labeled probes were prepared using the DIG RNA labeling kit
and detected using the DIG Nucleic Acid Detection kit (Boehringer
Mannheim). The template for the RNA probe was the mouse Su(Fu)
EST cDNA clone 513730 (987 bp) that contains exons 1 through 9.
Speci¢city of the reaction was monitored by comparison to samples
hybridized to sense probes.
2.6. Epitope-tagged constructs
Myc-SU(FU) and HA-GLI1, both in pCMV-5, have been described
[3]. The myc-tagged constructs for the transcription variants were
generated by cloning cDNAs into the pGEM-T vector (Promega).
In detail, a BstEII (nucleotide 327)^SalI (behind the STOP codon)
fragment from near full-length SU(FU)-XL was cloned into myc-
SU(FU), and EcoNI (nucleotide 751)^SalI fragments of SU(FU)-Tt
and SU(FU)-Lk were ligated into myc-SU(FU)-XL.
2.7. Transient transfections and Western blotting
10 Wg each of the tagged GLI and SU(FU) constructs were trans-
fected into a near con£uent 15-cm culture dish with 293 kidney carci-
noma cells using 75 Wg of polyethyleneimine (Sigma Chemicals) as a
transfecting agent in 12 ml serum-free medium. After 36 h cells were
harvested and lysed in 1% Triton X-100. The lysates were precleared
one time over protein A/G-agarose preincubated with goat serum and
then precipitated with mouse anti-myc monoclonal antibody 9E10 or
rabbit anti-mouse antiserum. After electrophoretic separation on a
reducing 10% SDS^PAGE gel and blotting onto PVDF membrane,
myc-tagged proteins were detected by rabbit anti-myc antiserum, fol-
lowed by incubation with a peroxidase-conjugated secondary anti-
body.
2.8. Sequencing of the coding regions of SU(FU) in SHFM3 patients
mRNA was obtained from transformed SHFM3 patient B cell lines
as described in Section 2.4. cDNA and subsequently PCR products of
the coding regions were generated and sequenced. The ¢rst 49 nucleo-
tides of the SU(FU) coding region were not included in the cDNA so
that was sequenced from genomic DNA instead. At least 13 clones
from each patient sample were analyzed. In addition, exon 1 from the
patients was sequenced from genomic DNA. Single-strand conforma-
tional polymorphism (SSCP) analysis was performed on PCR frag-
ments ampli¢ed from genomic DNA as previously described [23].
3. Results and discussion
3.1. Chromosomal localization and genomic organization of the
human SU(FU) and mouse Su(Fu) genes
Previously, we identi¢ed the human and murine homologs
of the Drosophila signal transducer molecule Su(Fu) [3]. To
determine the chromosomal localization of the human
SU(FU) gene, a radiation hybrid mapping panel was
screened. The SU(FU) gene was localized to chromosome
10q24 between the markers AFM183XB12 and D10S192,
with a distance of 0.10 cR from AFM183XB12 (lods 3.0).
In order to investigate the gene structure, we identi¢ed BAC
clones containing both the human SU(FU) and the murine
Su(Fu) genes and determined the exon^intron organization.
Both genes contain 12 exons with exon^intron boundaries at
identical positions (Table 1). The mouse Su(Fu) gene was
found to span approximately 100 kb (Fig. 1). The promoter
region contained no consensus TATA- or CAAT-boxes im-
mediately upstream of the putative transcriptional start site.
However, using the Transcription Start Site Wingender
database (TSSW) at UK HGMP Resource Centre
(www.hgmp.mrc.ac.uk) a promoter in this region with an ex-
cellent prediction value (LDF = 20.80) was found. When se-
quencing upstream of both the putative human and murine
promoters, the ATG-containing exon for the gene actin-re-
lated protein 1 (ARP1 [24] and Arp1 [25] in human and mouse,
respectively) was detected in opposite transcriptional orienta-
tion (Fig. 1). The two ATG initiation codons of the ARP1/
Arp1 and the SU(FU)/Su(Fu) genes are only 1.5 kb apart. In
addition, sequencing of the end of BAC 17986 revealed an
exon for the ADP ribosylation factor-like protein 3 (Arl3)
[26] downstream of the mouse Su(Fu) gene (Fig. 1). During
the course of these studies, genomic organization of the mouse
Table 1
Exon^intron boundaries of the human SU(FU) and mouse Su(Fu) genes
Exon Human exon Human intron Mouse exon Mouse intron (length)
1 1-ATGGCGTGTACTG-182 gtatgcTttgcag 1-ATGGCGTGTACTG-182 gtctgcTttgcag (3.7 kb)b
2 183-GTTGGGTCCATGA-317 gtgaagTtttcag 183-GTTGGGTCCATGA-317 gtgagtTtttcag (24 kb)b
3 318-GTTTACTAGTCAG-454 gtaggaTccacag 318-GTTTACTAGTCAG-454 gtaataTccacag (22 kb)b
4 455-AGAACATCTCCAG-597 gtgaggTcctcag 455-AGAACATCTCCAG-597 gtgaggTccacag (607 bp)a
5 598-ATCGTTTGCCTAT-683 gtgagtTccacag 598-ATTGTTTGCCCAT-683 gtgagtTccacag (226 bp)a
6 684-TGCTGGTCTGCAA-756 gtatgtTaagcagc 684-TGCTGGTCTGCAA-756 gtatgtTaagcagc (2.3 kb)b
7 757-GAGAGATGCAAAG-910 gtgggaTttgcag 757-GAGAGATGCAAAG-910 gttgagTttgcag (1419 bp)a
8 911-ACACAGTGGCCCC-1022 gtaagtTtcacag 911-ACACAGTGGCTCC-1022 gtaagtTtcacag (22 kb)b
9 1023-GAGCCGTCCTAAG-1157 gtgagcTctccag 1023-GAGCCGTCCTAAG-1157 gtgagcTccccag (1.6 kb)b
10 1158-GGGCAGTTTACAA-1296 gtgagaTtcacag 1158-GGGCAGTTTACAA-1296 gtgagaTtcccag (9.9 kb)b
11 1297-ATTCTGTTGAdTGAGGAA-1365 gtaagcTccacag 1297-ATTCTGTGAGGAA-1365 gtgagcTtcacag (1.9 kb)b
12 1366-TTCAAAT 1366-TTTAAATCTGCAG-4309
The translational start site is numbered as nucleotide 1 since the transcriptional start site is not exactly de¢ned. Exon 1 contains approximately
an additional 150 bp 5P of the translational start site.
aFully sequenced.
bPartially sequenced.
cThe italicized ag is that alternatively used in SU(FU)-XL.
dThe double-underlined TGA is the STOP codon used in SU(FU)-Lk.
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Su(Fu) gene was published [27]. However, their published
gene structure was not complete in that several intron sizes
were not determined and that the last exon (exon 12) was not
identi¢ed.
Mining the GenBank mouse EST database, several Su(Fu)
EST clones were found demonstrating expression in a wide
range of tissues: fertilized egg, embryos from day post coitum
(dpc) 8, 10^11, and 13, head from day post natum (dpn) 6,
skin from dpn 10, adult testis, heart, kidney, B cell, and mam-
mary gland. Four mouse Su(Fu) ESTs were sequenced and
their structures are shown in Fig. 1B. The combined EST
cDNAs extend over 4400 bp, which ¢ts well with the
mRNA size seen on Northern blots (V4.5 kb, data not
shown). The predicted AUG codon of the translational initia-
tion ¢ts the Kozak consensus sequence. The clones 1224813
and 963990 that extend the most 3P, as well as a number of
other human and mouse ESTs in the GenBank end at the
same position. However, no consensus AATAAA polyadenyl-
ation signal was found at the expected position. Possibly, an
ATTAAA sequence about 15 bp upstream of the polyA tract,
conserved in both human and mouse, is used instead.
3.2. SU(FU) mRNA isoforms
We screened a panel of cDNAs from various tissues of ap-
parently healthy donors for expression of variants of
SU(FU). One SU(FU) variant found had a tri-nucleotide
insertion after nucleotide 756 of the coding sequence resulting
in an extra glutamine after amino acid 252 resulting in a
protein with 485 amino acids. This insertion created a novel
EcoNI cleavage site that allowed easy detection of this var-
iant, which we called SU(FU)-XL. SU(FU)-XL was found to
be expressed in ¢ve of seven tissues tested with a relative
abundance varying from roughly 10% to 50% of total
SU(FU) (Fig. 2). This variant is due to an AG di-nucleotide
one nucleotide upstream of the standard AG splice acceptor
site in the end of intron 6 (Table 1). Use of this AG as an
alternative splice acceptor will introduce an extra CAG codon
in the mRNA product as seen in SU(FU)-XL.
We found two additional splice variants (Fig. 2), one of
them, SU(FU)-Lk, was expressed in peripheral leukocytes,
the other one, SU(FU)-Tt, in testes. By DNA sequencing it
was found that SU(FU)-Lk is lacking exon 10, and that the
downstream sequence has a shifted reading frame resulting in
a STOP codon after two amino acids. This results in a protein
with 388 amino acids. SU(FU)-Tt has an extra exon after
exon 8 (exon 8a), which encodes 19 amino acids followed
by a STOP codon resulting in a protein containing 359 amino
acids.
Fig. 1. Structure of the mouse Su(Fu) gene and cDNAs. A: The mouse Su(Fu) gene as assembled from mapping and partial sequencing of
BAC clones 17985 and 17986. Boxes indicate position of exons. Filled and un¢lled boxes indicate coding and non-coding regions, respectively.
Arrows indicate direction of the transcriptional unit for Su(Fu) and the linked upstream gene for Arp1 and the downstream gene for Arl3.
Only the exon containing the ATG translational start of Arp1 and the exon after the ATG-containing exon of Arl3 have been mapped and se-
quenced. Double arrowheads indicate start and end of BAC clones. Not all sites of the indicated enzymes have been mapped. E, EcoRI;
B, BamHI; H, HindIII; K, KpnI; Xb, XbaI; Sm, SmaI. B: Structure of the sequenced mouse Su(Fu) EST cDNAs 1195307 (mammary gland),
513730 (testis), 1224813 (heart), and 963990 (mammary gland), from the IMAGE consortium collection. Numbers 1 through 12 indicate the
Su(Fu) exons drawn to scale for a full-length mRNA transcript. ATG and TAG indicate the translational start and stop, respectively. The
thick lines represent the structural composition of each of the four EST clones positioned relative to the hypothetical full-length transcript. The
following EMBL/GenBank accession numbers have been assigned: AJ308627 (exon 1), AJ308628 (exon 2), AJ308629 (exon 3), AJ308630 (exon
4^6), AJ308631 (exon 7^8), AJ308632 (exon 9), AJ308633 (exon 10), AJ308634 (exon 11), AJ308635 (exon 12), AJ308626 (1195307), AJ308625
(513730), AJ308624 (1224813), and AJ308636 (963990).
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We also screened a panel of tumor cell xenograft cDNAs
(two breast, two lung, two colon, one prostate and one pan-
creatic carcinoma sample) and cDNA samples from a panel of
dpc 13.5 mouse embryonic tissues (lung, intestine, skeletal
muscle, heart, liver, eye, brain, spinal cord, tongue, kidney,
whole limb, skin) and we detected the normal SU(FU)/Su(Fu)
transcripts but no variants except SU(FU)-XL (data not
shown).
Functional analysis of these SU(FU) variants was per-
formed by assessing their potential to co-precipitate GLI1,
one of the physiological binding partners of SU(FU). N-ter-
minally myc-tagged versions of all SU(FU) variants and a
hemaglutinin-tagged version of GLI1 (HA-GLI) were trans-
fected into 293 cells. With an antibody against HA we could
co-precipitate myc-SU(FU) or myc-SU(FU)-XL, but not myc-
SU(FU)-Lk or myc-SU(FU)-Tt as detected by an anti-myc
antibody after Western blotting (Fig. 3). Thus, the two or-
gan-speci¢c expression variants SU(FU)-Lk and SU(FU)-Tt
might provide additional regulatory mechanisms to Hedgehog
signaling since these variants lack the ability of binding GLI1.
Thereby, GLI1 could be uncoupled from one of its cytoplas-
mic retention mechanisms.
Another transcriptional variant has been described [4] that
is expressed predominantly in testis and has the N-terminal
432 amino acids in common with the standard SU(FU) fol-
lowed by a STOP codon.
3.3. Expression of Su(Fu) during mouse embryogenesis
We analyzed mouse embryos in the time range between dpc
8.5 and dpc 15.5 for expression of Su(Fu) by whole mount in
situ hybridization. In particular, at dpc 10.5 and 11.5, we
observed an intense ubiquitous staining where the neural
tube and the forming CNS stained strongest. Only the liver
appeared to be negative. For the other stages however, we
found that certain tissues expressed Su(Fu) with considerably
stronger intensity than the ubiquitous reactivity of the em-
bryos. At dpc 8.5 and 9.5 we detected Su(Fu) in the neural
Fig. 2. Human SU(FU) variant transcripts. A: RT-PCR of a
SU(FU) fragment containing exons 5 through 9 from various tis-
sues. Tt and Lk indicate the respective variants. The other minor
bands in lane 3 and lane 4 represent PCR products that are not re-
lated to SU(FU). B: Same as in A, after EcoNI digestion. The low-
er band represents the EcoNI susceptible SU(FU)-XL variant. Since
the mobility of the EcoNI-digested fragment equals the mobility of
the SU(FU)-Lk band, lane 8 was omitted here. Lane 1, thymus;
2, prostate; 3, spleen; 4, testis; 5, colon; 6, ovary; 7, small intes-
tine; 8, peripheral leukocytes. C: Sequence of the intron 8a in
SU(FU)-Tt. The italicized letters signify the £anking exons 8 and 9.
Fig. 3. Myc-SU(FU)-Lk and myc-SU(FU)-Tt cannot co-precipitate
HA-GLI1. 10 Wg each of HA-GLI1 and myc-SU(FU)-Lk (lane 1),
myc-SU(FU)-Tt (lane 2), myc-SU(FU)-XL (lane 3) and myc-
SU(FU) (lane 4) were transfected into 293 cells. Lysates were pre-
cipitated with anti-myc (A) and anti-HA (B) antibodies and blotted
with anti-myc antiserum. Molecular weight markers (kDa) are to
the left of the blots. The arrowhead next to blot B indicates the po-
sition of the co-precipitated myc-SU(FU)-XL and myc-SU(FU).
Fig. 4. Whole mount in situ hybridization of mouse embryos with a
Su(Fu) antisense probe. A: dpc 8.5. B: dpc 9.5, lateral view.
Hindlimb (h), heart (he), mandibular arch (m), somites (s), the mes-
enchyme surrounding the prospective mouth cavity (*). C: dpc 9.5,
lateral view, prior to clearance with glycerol. Neural tube (nt).
D: dpc 10.5, dorsal view. Brain vesicles (b). E: dpc 10.5, dorsal
view of the tail after removal of the skin. Dorsal root ganglia (drg).
F: dpc 9.5, sagittal view. Dorsal aorta (da), intersegmentary arteries
(is). G: dpc 13.5, sagittal view. Spinal cord (sc), brain (b), mandible
(m), tongue (t), genital tubercle (g), mesenchyme close to the verte-
brae (v). H^J: Staining of the mesenchyme adjacent to the ossi¢ca-
tion zone of the digits in the hindlimb at dpc 13.5 (H), 14.5 (I),
15.5 (J). The arrows point to the Su(Fu) expressing areas that move
distally with time. K: dpc 14.5 sagittal section of the snout. Tongue
(t), most distal part of the snout (arrow). L: dpc 15.5, sagittal view
of the dorsal part of the thorax. The arrows point to the tracheoles.
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tube and in the somites (Fig. 4A^C). At dpc 9.5 Su(Fu) was
expressed further in the heart and the dorsal artery as well as
in the intersegmentary arteries (Fig. 4C,F), in the bud of the
hindlimb (Fig. 4B,C), in the branchial arches (Fig. 4B,F), and
in the mesenchyme of the trunk and of the head surrounding
the prospective mouth cavity (Fig. 4B). Su(Fu) expression in
the neural tissues persisted through the entire observed period.
At dpc 10.5 Su(Fu) was expressed in all brain vesicles (Fig.
4D) and in the dorsal root ganglia (Fig. 4E) as detected after
removal of the skin. At all later stages, the brain and the
spinal cord were stained with high intensity (Fig. 4G). The
expression of Su(Fu) in the somites persisted as well ; however,
from dpc 10.5 only the sclerotome and the sclerotome-derived
tissues were stained. The mesenchyme surrounding the ossify-
ing part of the vertebrae expressed Su(Fu) from dpc 12.5 (Fig.
4G and [3]) and of the ribs from dpc 13.5 [7]. Like in the
somite-derived skeletal parts and even in the digits, the ex-
pression of Su(Fu) was observed to parallel the progress of
ossi¢cation as the area that expresses Su(Fu) was migrating
distally during the course of development (Fig. 4H^J). The
expression of Su(Fu) in the branchial arches was continuing
within the maxilla, mandible and in the tongue and disappear-
ing from dpc 12.5 onwards when the mouth cavity was closed,
with at dpc 15.5 only tongue being stained (Fig. 4K). Through
the entire observed period, Su(Fu) was expressed in the genital
tubercle (Fig. 4G) and from dpc 13.5 in the mesenchyme
surrounding the developing tracheoles of the lung (Fig. 4L).
The sites of expression grossly coincide with that of other
members of the Hedgehog signaling pathway, in particular
with the expression of Gli3 [3]. However, in detail, this over-
lap is not found in all cases. Three other reports have inves-
tigated Su(Fu) expression in the mouse embryo [4,7,27] and
our data extend and con¢rm these studies.
3.4. Examination of DNA and RNA from SHFM3 patients for
mutations in the SU(FU) gene
The human SU(FU) gene is located in a region on 10q24
where the locus for the genetic disorder SHFM3 has been
mapped.
To investigate the hypothesis that SU(FU) would be the
gene involved in this syndrome, we initially screened ¢ve un-
related SHFM3 patients by Southern analysis with four re-
striction enzymes (EcoRI, HindIII, BglII, and, PstI). No signs
of gross alterations of the SU(FU) locus were seen (data not
shown). For a more detailed analysis, we sequenced a number
of cDNA clones of SU(FU) from B cell lines derived from
two unrelated heterozygous SHFM3 patients. No di¡erences
from the normal sequence were observed over the entire cod-
ing region (data not shown). In addition, SSCP analysis was
conducted on exons 2, 4, and 8^12 on the two probands from
the linked families as well as six other unrelated individuals.
Again, no alterations were observed (data not shown). With
our approach, however, mutations in the promoter or in
introns that would a¡ect the transcriptional regulation or
splicing of SU(FU) would not have been detected. Therefore,
although the possibility has decreased, the SU(FU) gene
can at this point not formally be excluded as a candidate gene
for the SHFM3 syndrome and additional studies are needed.
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